TY - JOUR
T1 - Nanoparticle-based drug delivery to the vagina
T2 - A review
AU - Ensign, Laura M.
AU - Cone, Richard
AU - Hanes, Justin
N1 - Funding Information:
This work was supported by National Institute of Health grants R01HD062844 (J.H., R.C., L.M.E.), R33AI079740 (J.H. and R.C.), R01EB015031 (J.H.), and the Johns Hopkins University Center for AIDS Research 1P30AI094189 (L.M.E.). The mucus penetrating particle technology is being developed by Kala Pharmaceuticals. Dr. Hanes is a co-founder of Kala. Drs. Hanes and Cone own company stock, which is subject to certain restrictions under University policy. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
PY - 2014/9/28
Y1 - 2014/9/28
N2 - Vaginal drug administration can improve prophylaxis and treatment of many conditions affecting the female reproductive tract, including sexually transmitted diseases, fungal and bacterial infections, and cancer. However, achieving sustained local drug concentrations in the vagina can be challenging, due to the high permeability of the vaginal epithelium and expulsion of conventional soluble drug dosage forms. Nanoparticle-based drug delivery platforms have received considerable attention for vaginal drug delivery, as nanoparticles can provide sustained release, cellular targeting, and even intrinsic antimicrobial or adjuvant properties that can improve the potency and/or efficacy of prophylactic and therapeutic modalities. Here, we review the use of polymeric nanoparticles, liposomes, dendrimers, and inorganic nanoparticles for vaginal drug delivery. Although most of the work toward nanoparticle-based drug delivery in the vagina has been focused on HIV prevention, strategies for treatment and prevention of other sexually transmitted infections, treatment for reproductive tract cancer, and treatment of fungal and bacterial infections are also highlighted.
AB - Vaginal drug administration can improve prophylaxis and treatment of many conditions affecting the female reproductive tract, including sexually transmitted diseases, fungal and bacterial infections, and cancer. However, achieving sustained local drug concentrations in the vagina can be challenging, due to the high permeability of the vaginal epithelium and expulsion of conventional soluble drug dosage forms. Nanoparticle-based drug delivery platforms have received considerable attention for vaginal drug delivery, as nanoparticles can provide sustained release, cellular targeting, and even intrinsic antimicrobial or adjuvant properties that can improve the potency and/or efficacy of prophylactic and therapeutic modalities. Here, we review the use of polymeric nanoparticles, liposomes, dendrimers, and inorganic nanoparticles for vaginal drug delivery. Although most of the work toward nanoparticle-based drug delivery in the vagina has been focused on HIV prevention, strategies for treatment and prevention of other sexually transmitted infections, treatment for reproductive tract cancer, and treatment of fungal and bacterial infections are also highlighted.
KW - Cervical cancer
KW - HIV PrEP
KW - Microbicides
KW - Mucosal vaccines
KW - Sexually transmitted infections
UR - http://www.scopus.com/inward/record.url?scp=84906781659&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906781659&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2014.04.033
DO - 10.1016/j.jconrel.2014.04.033
M3 - Review article
C2 - 24830303
AN - SCOPUS:84906781659
SN - 0168-3659
VL - 190
SP - 500
EP - 514
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -